Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Per-oral Endoscopic Myotomy (POEM) in Patients With Postfundplication Dysphagia (VADYSMA)

8. november 2026 oppdatert av: Prof. Jan Martinek, MD, PhD, AGAF, Institute for Clinical and Experimental Medicine

A Prospective Pilot Trial of Per-oral Endoscopic Myotomy (POEM) in Patients With Postfundplication Dysphagia (VADYSMA Trial)

Laparoscopic fundoplication represents the standard antireflux procedure, when conservative measures fail. However, any type of fundoplication may be accompanied by adverse events. Postfundoplication dysphagia (PFD) may hamper results of anti-reflux surgery. Endoscopic pneumatic dilation has been considered as the first line treatment option for persistent PFD. However, studies have not confirmed its effectiveness in this indication. Peroral endoscopic myotomy (POEM) became a standard treatment for the management of esophageal achalasia and moreover has also been assessed in a small cohort of patients with refractory PFD and some patients achieved significant treatment success. The investigators plan to perform a prospective international cohort multicenter study assessing the efficacy of POEM in patients with persistent and severe PFD.

Studieoversikt

Status

Rekruttering

Studietype

Intervensjonell

Registrering (Antatt)

30

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Trnava, Slovakia, 91701
        • Har ikke rekruttert ennå
        • University Hospital Trnava
        • Ta kontakt med:
        • Ta kontakt med:
    • Slovakia
      • Martin, Slovakia, Slovakia, 03601
        • Rekruttering
        • Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital Martin,
        • Ta kontakt med:
        • Ta kontakt med:
      • Brno, Tsjekkia, 60200
        • Rekruttering
        • St. Anne's University Hospital Brno, Czech Republic
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Patients after laparoscopic fundoplication procedure by Nissen (total, 360°), Dor (anterior, 180°) or Toupet (posterior, 270°) for gastroesophageal reflux disease no later than 10 years before enrolment.
  2. Refractory (> 6 months) and severe dysphagia after fundoplication procedure defined as an Eckardt score ≥3 and Mellow - Pinkas score ≥2 at baseline.
  3. X-ray (contrasted radiographic examination of the esophagus) characterized by both: a.) tapered narrowing of the distal esophagus and GEJ; b.) partial/total stagnation of the contrast solution above the GEJ
  4. Endoluminal planimetry: EGJ-DI < 3 mm2/mmHg (with 40ml)
  5. Age above 18 years
  6. Signed informed consent form

Exclusion Criteria:

  1. No previous attempt with at least one prokinetic drug
  2. Previous esophageal myotomy (open, laparoscopic or endoscopic)
  3. Primary esophageal motility disorder (achalasia etc.)
  4. Active erosive esophagitis
  5. Active peptic ulcer disease
  6. Esophageal stricture (peptic, malignant, other)
  7. Partial or complete supradiaphragmatic migration of the wrap and/or stomach (Hinder Type III - IV), Large hiatal hernia more than 5 cm
  8. Known eosinophilic esophagitis
  9. Severe coagulopathy
  10. Esophageal or gastric varices
  11. Advanced liver cirrhosis (Child B or Child C)
  12. Pregnancy or puerperium
  13. Malignant or pre-malignant esophageal diseases (dysplasia): patients with a history of such disease after its cure are eligible for enrolment
  14. Any other condition, which in the opinion of the investigator would interfere with study requirements
  15. Known gastroparesis

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: POEM arm

Patients, who will undergo peroral endoscopic myotomy for postfundoplication dysphagia

All procedures will be performed by an experienced endoscopist, with a sufficient experience in "third space" endoscopy (at least 100 POEMs) under general anesthesia (internal preoperative examination is necessary) with a high-definition endoscope, fitted with a plastic distal attachment. Before the procedure, the patients will be administered intravenous antibiotics. Exclusively CO2 will be used for insufflation. POEM will be performed in a similar way as in patients with achalasia - the procedure consists of 4 steps: (1) mucosal incision and tunnel entry, (2) submucosal tunneling, (3) myotomy, and (4) closure of the mucosal entry with endoscopic clips or other closure devices. Perioperative protocol might differ according the usual way of performing POEM in a given center.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Efficacy POEM in patients with postfundoplication dysfagia
Tidsramme: 6 months

The primary outcome will be proportion of patients with treatment success defined as Eckardt score ≤ 2 and its decrease by at least 1 point after POEM at 6 months

6 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Eckardt score
Tidsramme: At baseline, 3, 6 and 12 months

The Eckardt score is the grading system used for the evaluation of severity of symptoms in patients with esophageal achalasia. Four symptoms are assessed (dysphagia, regurgitation, chest pain and weight loss) and their severity ranges from 0 (no symptom) to 3 (with every meal). Total score is their sum and ranges from 0 to 12

At baseline, 3, 6 and 12 months
Mellow - Pinkas score
Tidsramme: At baseline, 3, 6 and 12 months

The Mellow - Pinkas score is used to assess dysphagia grade before and after the interventions. Total score ranges from 0 to 3 (0 = able to eat normal diet, 1 = able to swallow some solid foods, 2 = able to swallow only semi solid foods, 3 = able to swallow liquids only)

At baseline, 3, 6 and 12 months
PAGI-QOL score (Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life)
Tidsramme: At baseline, 3, 6 and 12 months

The PAGI-QoL questionnaire contains of 30 items with five subscales: (1) daily activities; (2) clothing; (3) diet/food habits; (4) relationship; and (5) psychological well-being and distress. Each item is scored on a 6-point Likert scale, with response options ranging from 0 (none) to 5 (severe problem all of the time). Subscale scores are calculated by averaging the item responses. A total score is calculated by averaging subscale scores. Higher score means impairment in quality of life.

At baseline, 3, 6 and 12 months
GERD-RHQL score (Gastroesophageal Reflux Disease Health-related Quality of Life)
Tidsramme: At baseline, 3, 6 and 12 months

The GERD-HRQL questionnaire was developed and validated to measure changes of typical GERD symptoms such as heartburn and regurgitation in response to surgical or medical treatment. Higher (greater) possible score means worst symptoms - ranging from 0 to 75.

At baseline, 3, 6 and 12 months
Integrated Relaxation Pressure (IRP)
Tidsramme: At baseline, at 6 months

High resolution manometry - Median IRP recorded from 10 supine swallows, measured in mmHg. A value >15 mmHg indicates EGJ outflow obstruction.

At baseline, at 6 months
Endoluminal planimetry (Endoflip)
Tidsramme: At baseline, ať 6 months

Pyloric distensibility measured by impedance planimetry (EndoFLIP device)

At baseline, ať 6 months
Esophagogram
Tidsramme: At baseline, at 6 months

Esophagogram provides valuable information of the fundoplication, better appreciate a paraesophageal hernia and information on esophageal emptying.

Patients will be advised overnight fasting prior to timed barium esophagogram. A contrast agent (e.g. barium, usually 100 to 250 mL) is ingested orally within 15-20 seconds. Left posterior oblique X-ray will be taken 2 and 5 minutes after contrast agent ingestion. Maximum esophageal width and column hights will be recorded at 2 and 5 minutes.

At baseline, at 6 months
Eckardt score
Tidsramme: At baseline, 3 and 12 months

The Eckardt score is used to assess the severity of achalasia symptoms. It is based on the four main symptoms of achalasia: dysphagia, regurgitation, chest pain and weight loss. Each symptom has four levels of severity: none = 0 point, occasional = 1 point, daily = 2 points, each meal = 3 points. The sum of the points gives the final score. Final score scale: 0 (best) - 12 (worst). Treatment success is defined as a decrease of Eckardt score by at least 1 point and an overall Eckardt score ≤ 2.

At baseline, 3 and 12 months
GERD
Tidsramme: At baseline, 3, 6 and 12 months

Presence of reflux esophagitis based on endoscopy findings.

At baseline, 3, 6 and 12 months
Esophageal 24h-Hour pH metry
Tidsramme: At 3 months after procedure

An esophageal pH test measures how often stomach acid enters to the esophagus. It also measures how long the acid stays there. The test involves placing a catheter into the esophagus. The catheter or device will measure an acid level (known as pH level) for 24 hours. Post-POEM Esophageal acid exposure (DeMeester score, proportion of time with pH below 4)After

At 3 months after procedure
PPI/H2 antagonists
Tidsramme: At baseline, 3, 6 and 12 months

PPI's and/or H2 antagonists use before and after procedure (POEM).

At baseline, 3, 6 and 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. april 2025

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. juni 2027

Datoer for studieregistrering

Først innsendt

10. februar 2025

Først innsendt som oppfylte QC-kriteriene

6. mars 2025

Først lagt ut (Faktiske)

12. mars 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere